Evidence map›Paper›PMID 41486630›Full record

Trial reportBritish journal of haematology2026

High pretreatment peripheral blood T-cell receptor clonality as a predictor of prolonged response in immune thrombocytopenia.

Paul Schmidt-Barbo, Christoph Schultheiss, Annaïse J Jauch, Donjetë Simnica, Gerda Silling, Mathias Hänel, Jörg Chromik, Thomas Stauch, Karolin Trautmann-Grill, Roland Repp and 15 more

Abstract readRandomized Controlled TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in British journal of haematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Paul Schmidt-BarboDivision of Medical Oncology, University Hospital Basel, Basel, Switzerland.
Christoph SchultheissDivision of Medical Oncology, University Hospital Basel, Basel, Switzerland.
Annaïse J JauchDivision of Haematology, University Hospital Basel, Basel, Switzerland.ORCID https://orcid.org/0009-0004-8391-1666
Donjetë SimnicaDivision of Clinical Pharmacology, Ludwig Maximilian University Hospital, Ludwig Maximilian University Munich, Munich, Germany.
Gerda SillingDepartment of Haematology, Oncology, Haemostaseology and Stem Cell Transplantation, Faculty of Medicine, RWTH Aachen University, Aachen, Germany.
Mathias HänelDepartment of Internal Medicine III, Klinikum Chemnitz, Chemnitz, Germany.ORCID https://orcid.org/0000-0002-4767-3275
Jörg ChromikDepartment of Medicine II, Haematology and Oncology, Goethe University Frankfurt, University Hospital, Frankfurt, Germany.
Thomas StauchDepartment of Internal Medicine II, Haematology and Oncology, University Hospital Jena, Jena, Germany.
Karolin Trautmann-GrillDepartment of Internal Medicine I, University Hospital Dresden, Dresden, Germany.
Roland ReppMedical Department 2, City Hospital Kiel, Kiel, Germany.
Clemens SchulteGemeinschaftspraxis für Hämatologie und Onkologie, Dortmund, Germany.
Bastian FleischmannOnkologisches Zentrum Donauwörth, Donauwörth, Germany.
Manfred WelslauOnkologie Aschaffenburg, Aschaffenburg, Germany.
Martina StauchHaematology, Oncology/Haemostaseology Kronach, Kronach, Germany.
Claudia QuieringNovartis Pharma GmbH, Nürnberg, Germany.
Frank RichterNovartis Pharma GmbH, Nürnberg, Germany.
Tamara TesanovicNovartis Pharma GmbH, Nürnberg, Germany.
Sabine JahnNovartis Pharma GmbH, Nürnberg, Germany.
Andreas HolbroDivision of Haematology, University Hospital Basel, Basel, Switzerland.
Jakob R PasswegDivision of Haematology, University Hospital Basel, Basel, Switzerland.
Axel MatzdorffDepartment of Medicine II, Asklepios Clinic Uckermark, Schwedt, Germany.
Mathias RummelDepartment of Haematology, Clinic for Haematology and Medical Oncology, Justus Liebig University Hospital Giessen, Giessen, Germany.
Oliver MeyerDRK Blood Service NSTOB, Springe, Germany.
Falk NimmerjahnDivision of Genetics, Department of Biology, Friedrich Alexander University Erlangen-Nürnberg, Erlangen, Germany.
Mascha BinderDivision of Medical Oncology, University Hospital Basel, Basel, Switzerland.ORCID https://orcid.org/0000-0003-0663-3004

Funding

Jacques und Gloria Gossweiler StiftungMertelsmann FoundationNovartisSchweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung 10.001.762
6 · The paper itself

Abstract

Left panel: Scheme of the XPAG-immune thrombocytopenia trial. The dexamethasone (DEX) arm consisted of DEX 40 mg/day for days 1-4 for one to three cycles every 28 days to a maximum of 12 weeks, cycles 2 + 3 were optional. Patients randomised to eltrombopag (ETB) + DEX received eltrombopag in combination with a short course of high-dose DEX beginning on day 1 (40 mg/day during days 1-4). The starting dose of ETB was 50 mg/day for 2 weeks; thereafter, the ETB dose was increased by 25 mg for all patients who did not achieve the target platelet count of ≥50 × 10

Indexed as

Purpura, Thrombocytopenic, IdiopathicReceptors, Antigen, T-CellAdultAgedBenzoatesDexamethasoneFemaleHumansHydrazinesMaleMiddle AgedPyrazolesTreatment OutcomeBenzoatesDexamethasoneeltrombopagHydrazinesPyrazolesReceptors, Antigen, T-CellBCRbiomarkereltrombopagimmune repertoireITPTCR

Identifiers

PMID41486630
PMCPMC12916192

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.